

Andreas F Hottinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1004616/publications.pdf>

Version: 2024-02-01

31
papers

3,597
citations

687363

13
h-index

580821

25
g-index

35
all docs

35
docs citations

35
times ranked

5156
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	1.6	67
2	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1269-1278.	0.8	20
3	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	1.2	1
4	MEVITEM® a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. <i>Neuro-Oncology</i> , 2021, 23, 1949-1960.	1.2	20
5	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	1.6	3
6	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 679702.	2.8	8
7	Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 133.	5.2	7
8	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 671972.	2.8	14
9	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. <i>Annals of Neurology</i> , 2020, 87, 22-29.	5.3	30
10	Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
11	Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101310.	0.4	3
12	Glioma patient-reported outcome assessment in clinical care. <i>Lancet Oncology</i> , The, 2020, 21, e230.	10.7	2
13	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 912-917.	1.2	59
14	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. <i>Swiss Medical Weekly</i> , 2020, 150, w20256.	1.6	5
15	COVID-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii24-ii24.	1.2	0
16	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
17	Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. <i>Neuro-Oncology Practice</i> , 2019, 6, 264-273.	1.6	14
18	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 3.	4.2	83

#	ARTICLE	IF	CITATIONS
19	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	7.1	135
20	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	7.4	1,619
21	Current Standards of Care in Glioblastoma Therapy. , 2016, , 73-80.		7
22	Current management of low-grade gliomas. <i>Current Opinion in Neurology</i> , 2016, 29, 782-788.	3.6	26
23	Neurologic complications of immune checkpoint inhibitors. <i>Current Opinion in Neurology</i> , 2016, 29, 806-812.	3.6	179
24	Neurooncology: a Swiss army knife specialty. <i>Current Opinion in Neurology</i> , 2016, 29, 781.	3.6	0
25	Performance of ¹⁸ F-FET versus ¹⁸ F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2016, 18, 426-434.	1.2	143
26	Multilevel severe radiculopathy from an extraneural glioblastoma cervical metastasis. , 2016, 7, 1028.		4
27	Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. <i>Anticancer Research</i> , 2016, 36, 2359-64.	1.1	7
28	Recent developments and controversies in primary central nervous system lymphoma. <i>Current Opinion in Oncology</i> , 2015, 27, 496-501.	2.4	9
29	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	7.4	982
30	Standards of care and novel approaches in the management of glioblastoma multiforme. <i>Chinese Journal of Cancer</i> , 2014, 33, 32-39.	4.9	121
31	PET Imaging in Glioma. <i>PET Clinics</i> , 2013, 8, 117-128.	3.0	4